News & Press: Latest News

Leading Executives from Across the Country Urge Senate to Repeal the Device Tax

Wednesday, November 14, 2012   (0 Comments)
Share |

Washington, D.C. – A broad coalition of medical technology companies, physician groups, venture capital firms and leading associations today submitted a letter to Senate leadership urging policymakers to repeal the onerous medical device tax that threatens U.S. jobs, medical innovation and patient care. The Medical Device Manufacturers Association (MDMA), Medical Imaging & Technology Alliance (MITA) and the Advanced Medical Technology Association (AdvaMed) were among the 805 signatories that represent hundreds of thousands of medical technology jobs. Beginning January 1, 2013, the health care law will impose over $30 billion in new excise taxes on medical technology companies.

In coordination with the coalition letter, tomorrow more than 50 executives from across the United States representing the two million that work for and support the medical technology industry will meet with members of Congress to encourage them to protect research, development, investment and innovation by repealing the excise tax.

"We are already seeing the negative impact this onerous policy is having on jobs and innovation, and America’s med tech innovators can’t afford to find out what implementation of the device tax would bring,” said Mark Leahey, President and CEO of MDMA. "At a time when elected officials are looking for more manufacturing jobs based in innovative industries, repealing this tax is a win-win for patients and workers.”

"Without action from Congress, implementation of the medical device tax will cost our economy thousands of high paying jobs,” said Gail Rodriguez, Executive Director of MITA. "These job losses will directly impact patient access to the most advanced, life-saving medical technologies available.”

Employing more than 400,000 workers nationwide, the medical device industry generates approximately $25 billion in payroll, pays out salaries that are 40 percent higher than the national average ($58,000 vs. $42,000) and invests nearly $10 billion in research and development (R&D) annually.

"This damaging tax will force job cuts and investments in tomorrow’s treatments and cures,” said Stephen J. Ubl, President and CEO of AdvaMed. "Continued medical innovation is key to driving public health gains by reducing costs associated with chronic diseases like diabetes and obesity and catalyzing economic growth through healthier more productive people and by creating high quality manufacturing jobs. Simply put healthier lives mean healthy economies.”

The letter notes that the medical device industry is fueled by innovative companies, many of which are small businesses. In fact, 80 percent of them have less than 50 employees and 98 percent have less than 500 employees. The impact of the device tax is expected to be especially hard on smaller companies whose innovations are not immediately profitable.

To read a copy of the letter, click here.